Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals

Key PointsThe State Street SPDR S&P Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF carry identical 0.35% expense ratios.

When choosing between the State Street SPDR S&P Biotech ETF (XBI) and the State Street SPDR S&P Pharmaceuticals ETF (XPH), investors must weigh their risk tolerance against their desire for sector specificity. Both funds provide concentrated exposure to distinct healthcare sub-sectors within the industry.

Biotechnology stocks are notorious for their high-growth potential but also exhibit considerable price fluctuations. On the other hand, pharmaceutical companies generally offer a more stable investment option for those seeking healthcare exposure without the intense volatility typically associated with biotech firms still in early-stage clinical research.

To assess the risk profile of each ETF, analysts often examine the beta coefficient, which quantifies price volatility relative to the S&P 500. Beta is derived from analyzing monthly returns over the fund's history, typically spanning up to five years. For instance, over the past year, XBI has delivered a total return of 37.17%, while XPH has returned 29.60%. Both funds distribute dividends based on their trailing-12-month earnings.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at nasdaq.com →

More in Finance & Markets

Exports up by 10.84% to $8.4bn in Q1

Exports from the country increased by 10.84 percent during the first quarter of the current fiscal year as compared to the corresponding period of last year, Pakistan Bureau of Statistics (PBS)…

More from Sunday 4 October →